Results 11 to 20 of about 21,457 (213)

Dosing Biologic Drugs for Patients With Obesity: One Size Does Not Fit All. [PDF]

Arthritis Rheumatol
Arthritis &Rheumatology, EarlyView.
Balevic SJ, Gonzalez D, Meibohm B.
europepmc   +2 more sources

Benefits of Autoantibody Enrichment in Early Rheumatoid Arthritis: Analysis of Efficacy Outcomes in Four Pooled Abatacept Trials

Rheumatology and Therapy, 2023
Introduction The efficacy of abatacept is enhanced in anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF)-positive versus -negative patients with rheumatoid arthritis (RA).
Kaleb Michaud, Philip G. Conaghan, Sang Hee Park, Karissa Lozenski, Mirko Fillbrunn, Vadim Khaychuk, Elyse Swallow, John Vaile, Henry Lane, Ha Nguyen, Janet Pope   +10 more
doaj   +1 more source

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Global & Regional Health Technology Assessment, 2021
Purpose: The objective of this economic evaluation was to compare the cost per responder between upadacitinib and abatacept (intravenous [iv] or subcutaneous [sc]) in patients with moderate-to-severe Rheumatoid Arthritis (RA) in Italy.
Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi   +3 more
doaj   +1 more source

HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA

Arthritis Research & Therapy, 2021
Background Certain risk alleles associated with autoantibody-positive rheumatoid arthritis (RA) have been linked to poorer prognoses. In patients with autoantibody-positive RA, abatacept shows differential efficacy to tumor necrosis factor inhibitors ...
William Rigby, Jane H. Buckner, S. Louis Bridges, Marleen Nys, Sheng Gao, Martin Polinsky, Neelanjana Ray, Vivian Bykerk   +7 more
doaj   +1 more source

Persistence with Early-Line Abatacept versus Tumor Necrosis Factor-Inhibitors for Rheumatoid Arthritis Complicated by Poor Prognostic Factors

Journal of Health Economics and Outcomes Research, 2021
# Background Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by joint swelling and destruction that leads to severe disability. There are no clear guidelines regarding the order of therapies.
Xue Han, Francis Lobo, Michael S. Broder, Eunice Chang, Sarah N. Gibbs, David J. Ridley, Irina Yermilov   +6 more
doaj   +1 more source

Impact of the HLA-DRB1 shared epitope on responses to treatment with tofacitinib or abatacept in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2021
Objectives The aim of this study was to compare the clinical effectiveness of tofacitinib and abatacept and clarify the impact of the HLA-DRB1 shared epitope (SE) on responses to these treatments in patients with rheumatoid arthritis (RA).
Wataru Hirose, Masayoshi Harigai, Koichi Amano, Toshihiko Hidaka, Kenji Itoh, Kazutoshi Aoki, Masahiro Nakashima, Hayato Nagasawa, Yukiko Komano, Toshihiro Nanki, for the TOF-ABT Study Group   +10 more
doaj   +1 more source

Tocilizumab and Abatacept for the Treatment of Childhood Chronic Uveitis: A Monocentric Comparison Experience

Frontiers in Pediatrics, 2022
BackgroundOur study aimed to evaluate the efficacy of Tocilizumab and Abatacept for treating Childhood Chronic non-infectious Uveitis (CCU), resistant to anti-tumor necrosis factor (anti-TNF) treatment.MethodsThis is a monocentric retrospective charts ...
Ilaria Maccora, Ilaria Maccora, Sarah Abu Rumeileh, Franco Curci, Cinzia de Libero, Edoardo Marrani, Maria Vincenza Mastrolia, Ilaria Pagnini, Gabriele Simonini, Gabriele Simonini   +9 more
doaj   +1 more source

Interference of the T cell and antigen-presenting cell costimulatory pathway using CTLA4-Ig (abatacept) prevents Staphylococcal enterotoxin B pathology [PDF]

, 2017
Staphylococcal enterotoxin B (SEB) is a bacterial superantigen that binds the receptors in the APC/T cell synapse and causes increased proliferation of T cells and a cytokine storm syndrome in vivo.
Carter, Alun J, Green, A. Christopher, Griffiths, Gareth D, Jones, James T.A., Rijpkema, Sjoerd, Risdall, Jane E, Saraiva, Luisa, Taylor, Chris, Vessillier, Sandrine, Whitfield, Sarah J.C., Williamson, E. Diane   +10 more
core   +2 more sources

CD28 between tolerance and autoimmunity: The side effects of animal models [version 1; referees: 2 approved] [PDF]

, 2018
Regulation of immune responses is critical for ensuring pathogen clearance and for preventing reaction against self-antigens. Failure or breakdown of immunological tolerance results in autoimmunity.
A Aruffo, A Levine, A Paterson, A Schneider, B Salomon, C Brunstein, C Camperio, C Dendrou, C Lin, C Peterfy, D Franckaert, D Tyrsin, E Hui, E Mayer, F Lühder, G Burmester, G Freeman, G Suntharalingam, H Gmünder, H Ko, I McInnes, I Vogel, J Esensten, J Gross, J Kremer, J Vahl, K Haanstra, M Kishore, M Kunkl, M Tacke, M Vierboom, M Wagner, N Beyersdorf, N Dilek, N Ohkura, N Poirier, N Porciello, N Porciello, O Acuto, P Emery, P Linsley, P Martin, P Tabares, Q Zhang, R Westhovens, R Westhovens, R Zhang, R Zhang, R Zhang, S Bhela, S Khoury, S Weißmüller, S Yao, T Hünig, T Hünig, T Thauland, T Thaventhiran, X He   +57 more
core   +2 more sources

A nationwide survey on patient's versus physician's evaluation of biological therapy in rheumatoid arthritis in relation to disease activity and route of administration : the Be-Raise study [PDF]

, 2016
Objectives : Biological treatment of rheumatoid arthritis (RA) is one of the cornerstones of current treatment strategies for the disease. Surprisingly little information exists on whether the route of administration affects patients' treatment ...
Bert Vander Cruyssen, Dirk Elewaut, Herman Mielants, Jan Lenaerts, null null, Patrick Durez, René Westhovens, Sophie De Mits   +7 more
core   +4 more sources